Solventum Corporation
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that ad...
Latest News
7 hours ago · zacks.com
SOLV's Q3 Earnings: Can Growth Momentum Offset ERP-Related Headwinds?Solventum's Q3 results are likely to face ERP-related order reversals and tariff pressures, while MedSurg, Dental and Acera growth may have supported underlying performance.
4 days ago · zacks.com
Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseSolventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 days ago · zacks.com
Here's Why Solventum (SOLV) is a Strong Value StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
10 days ago · zacks.com
SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.TherapySolventum gains FDA clearance to combine Restrata Matrix with V.A.C. Therapy, potentially expanding wound care applications and supporting long-term growth.
12 days ago · globenewswire.com
SOLV Energy to Report Third Quarter 2026 Financial Results on November 12, 2026SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (“SOLV” or the “Company”) (Nasdaq: MWH) plans to report third quarter 2026 results on Thursday, November 12, 2026. Management will present results during a conference call at 8:30 a.m. Eastern time.
14 days ago · prnewswire.com
Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*First-of-its-kind clearance combines two advanced wound care technologies into one path for active healing to help streamline care and improve patient outcomes Clearance pairs innovative synthetic electrospun fiber matrix technology with an industry-leading negative pressure wound therapy to optimize healing EAGAN, Minn., Oct. 19, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata™ Synthetic Electrospun Fiber Matrix and Solventum™ V.A.C.
18 days ago · prnewswire.com
Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026EAGAN, Minn., Oct. 15, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its third quarter fiscal 2026 financial results on Thursday, November 5, 2026, after the U.S. financial markets close.
25 days ago · zacks.com
Can Solventum (SOLV) Keep the Earnings Surprise Streak Alive?Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
25 days ago · zacks.com
Why Solventum (SOLV) is a Top Value Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
2 months ago · seekingalpha.com
Solventum: Divestiture Unlocking Upside In A Spinoff Revaluation PlaySolventum trades at a significant discount to medical technology peers, with a forward P/E of ~13x and suppressed EV/EBITDA multiples. Management is executing a portfolio optimization, including a potential spin-off of the Health Information Systems segment to unlock value and reduce debt. Raised 2026 EPS guidance to $7.10-$7.20 and operating margins to 22.2%-22.7%, signaling margin expansion and improved free cash flow allocation.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove SOLV